NDATOPICALCREAM3 Generics Approved
Approved
Feb 2005
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Clinical Trials
3
Data completeness
5/8 — Partial
VANOS (fluocinonide) by Bausch + Lomb is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 2005.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VANOS (fluocinonide) is a potent topical corticosteroid cream approved for inflammatory and immune-mediated skin conditions including atopic dermatitis, mycosis fungoides, hand-foot skin reactions, and rash. It works as a corticosteroid hormone receptor agonist to reduce inflammation and immune response at the site of application. The drug has been on the market since 2005 and remains a standard-of-care option for moderate-to-severe dermatological conditions.
$0.026MPart D
LOE ApproachingLow commercial momentum with minimal Part D spending ($26K in 2023) and only 12 claims suggests a mature, niche product with declining team requirements as loss of exclusivity approaches.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Fusion The IVANOS-study
Started Mar 2012
102 enrolled
Spinal StenosisLow Back Pain
Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy
Started Sep 2011
34 enrolled
Breast Carcinoma
VANOS Cream and Skin Barrier Function
Started Jan 2009
25 enrolled
Atopic Dermatitis
Career Relevance
VANOS offers minimal career growth opportunity given its LOE-approaching lifecycle stage, negligible commercial footprint ($26K Part D spending), and zero linked job openings. Working on this product typically involves defensive strategies, generic competition management, or OTC transition planning rather than expansion or innovation work.
Worked on VANOS at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.